Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
about
Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsEffect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV InfectionPharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypesHigh CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population.Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populationsEvaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients.PharmGKB summary: Efavirenz pathway, pharmacokineticsAn Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS PatientsBeneficial effects of intravenous dexmedetomidine on cognitive function and cerebral injury following a carotid endarterectomy.Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.Pharmacogenomic implications of the evolutionary history of infectious diseases in AfricaCytochrome P450 pharmacogenetics in African populations: implications for public health.CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy.CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.Drug-Induced Tactile Hallucinations Beyond Recreational Drugs.Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.A 33-year-old patient with human immunodeficiency virus on antiretroviral therapy with efavirenz-induced complex partial seizures: a case report.CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana.Antiretroviral treatment for HIV infection: Swedish recommendations 2016.Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review.Incidence of neuropsychiatric side effects of efavirenz in HIV-positive treatment-naïve patients in public-sector clinics in the Eastern Cape.Disease burden and the role of pharmacogenomics in African populations.Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype
P2860
Q28069383-E693672C-3C41-4D61-8637-6A8723A3E6F8Q28548638-5ACA8204-814A-4FBC-BE43-C1E80E0351F1Q31150044-83B9B298-917B-4E86-ABE8-AF64B435B8B9Q33861268-E388CA5E-72A8-4A38-8AC5-7C65A9560429Q34826590-465A685E-4E1D-4C31-9468-12FF934B864DQ35142786-9C891544-7445-411A-8F77-96E4687CB24CQ35706069-2D2C91B1-1B8D-4BD4-BE79-7881961795B5Q36437792-81E20D7D-CB10-4D8E-839A-E363E885F9A4Q36640451-4B5EC4AD-A0F4-4C95-B9C0-71A216A39EC9Q37538760-C8123FFD-014D-4A07-A8DB-562F2D5030B7Q37737731-EAE02078-8BF6-4EB7-8F04-C132B307D43AQ38192688-CA7B1C06-AB21-408E-95CE-9ED43B7609EEQ38855121-68B20286-64BF-4053-94BB-AF5E6C7CF37CQ38859179-0F936A7B-67D7-44FD-9D3E-2FAA2B936C01Q38861140-20DA518B-B159-42B3-B3BC-AB9595280FABQ38956733-CD2C5C13-6D53-49F7-910C-C5F03F08F93EQ39039468-B7DB7895-964B-4D0E-A190-23F060A007B1Q40050910-390B7260-04FD-470E-BF1C-DDE46EB41678Q40117598-1AAF5CDD-E078-48B0-88B8-6CC9BE7AAAAFQ40129359-3BA6BFA6-B1DE-4431-A5A7-F8D27933D8E1Q40470257-5ECB2248-64EC-4DC3-BAED-0DC299DBCD71Q40563423-74A65FEF-CD15-425A-B649-4B4B438C3894Q41240864-3BB6282B-E6AD-489B-8F35-203A3AB8C0F9Q42592784-9DE2FD59-6DA8-4130-AE35-C65053DC7A4EQ52330065-CB435CDC-46C4-44EF-A025-3BE84F6FA1D6Q53759304-0E86C615-709A-441B-B612-3BEC775E8DCBQ54935902-76DA0359-65A7-48E6-8008-B25F8FD11B81Q58612379-9B994A25-ACAD-4FDF-ABA1-33FC0272E927
P2860
Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Influence of efavirenz pharmac ...... s: a prospective cohort study.
@ast
Influence of efavirenz pharmac ...... s: a prospective cohort study.
@en
Influence of efavirenz pharmac ...... s: a prospective cohort study.
@nl
type
label
Influence of efavirenz pharmac ...... s: a prospective cohort study.
@ast
Influence of efavirenz pharmac ...... s: a prospective cohort study.
@en
Influence of efavirenz pharmac ...... s: a prospective cohort study.
@nl
prefLabel
Influence of efavirenz pharmac ...... s: a prospective cohort study.
@ast
Influence of efavirenz pharmac ...... s: a prospective cohort study.
@en
Influence of efavirenz pharmac ...... s: a prospective cohort study.
@nl
P2093
P2860
P921
P356
P1476
Influence of efavirenz pharmac ...... s: a prospective cohort study.
@en
P2093
Alphonse Okwera
Deogratious Sebuwufu
Henry Luzze
Jackson K Mukonzo
Jasper Ogwal-Okeng
Neoline Nakasujja
Paul Waako
P2860
P2888
P356
10.1186/1471-2334-13-261
P577
2013-06-04T00:00:00Z
P5875
P6179
1014344279